May 25, 2018 09:24 AM EDT
Financing

Kezar and Xeris file for IPOs, join­ing May's march to the pub­lic mar­kets

Brittany Meiling

Adding to the flur­ry of IPOs be­fore May wraps up, two more biotechs filed in­ten­tions Thurs­day to go pub­lic: San Fran­cis­co’s Kezar Life Sci­ences hopes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

It's been three months with­out a biotech IPO

A service from the Financial Times